N-(3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)thiophen-2-carboxamide | 152459-89-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)thiophen-2-carboxamide
• 英文别名: Thiophene-2-carboxylic acid [3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-amide；N-[3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]thiophene-2-carboxamide
• CAS: 152459-89-7
• 化学式: C₂₀H₁₅N₅OS
• 分子量: 373.438
• InChiKey: MWZFSVMDXHMRHG-UHFFFAOYSA-N

物化性质

• 密度：
  1.389±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  108
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Organic Compounds
  申请人：Cooke Nigel Graham

  公开号：US20090156602A1

  公开（公告）日：2009-06-18

  The invention provides a pharmaceutical combination comprising: a) at least one agent selected from Bcr-Abl, Flt-3, FAK and RAF kinase inhibitors; and b) at least one JAK kinase inhibitor and a method for treating or preventing a proliferative disease using such a combination.

  本发明提供了一种药物组合物，包括：a) 至少一种选自Bcr-Abl、Flt-3、FAK和RAF激酶抑制剂的药物；以及b) 至少一种JAK激酶抑制剂，以及使用该组合物治疗或预防增生性疾病的方法。
• Devices delivering therapeutic agents and methods regarding the same
  申请人：Bhat D. Vinayak

  公开号：US20050125054A1

  公开（公告）日：2005-06-09

  Devices and methods for reducing, inhibiting, or treating restenosis and hyperplasia after intravascular intervention are provided. In particular, the present invention provides luminal prostheses which allow for sustained or controlled release of at least one therapeutic capable agent with increased efficacy to selected locations within a patient's vasculature to reduce restenosis. An intraluminal prosthesis may comprise an expandable structure and a source adjacent the expandable structure for releasing the therapeutic capable agent into a body lumen to reduce smooth muscle cell proliferation.

  本发明提供了用于减少、抑制或治疗血管内介入治疗后再狭窄和增生的设备和方法。特别是，本发明提供的管腔内假体可持续或受控地向患者血管内的选定位置释放至少一种疗效更佳的治疗剂，以减少血管再狭窄。腔内假体可包括一个可扩张结构和一个邻近可扩张结构的源，用于将治疗剂释放到体腔内，以减少平滑肌细胞增殖。
• Pyrimidinderivate und Verfahren zu ihrer Herstellung
  申请人：Novartis AG

  公开号：EP0564409B1

  公开（公告）日：2000-01-19
• DEVICES DELIVERING THERAPEUTIC AGENTS AND METHODS REGARDING THE SAME
  申请人：Avantec Vascular Corporation

  公开号：EP1539041A1

  公开（公告）日：2005-06-15
• COMBINATIONS OF JAK INHIBITORS
  申请人：Cooke Nigel Graham

  公开号：US20100280003A1

  公开（公告）日：2010-11-04

  The invention provides a pharmaceutical combination comprising: a) at least one agent selected from Bcr-Abl, Flt-3, FAK and RAF kinase inhibitors; and b) at least one JAK kinase inhibitor and a method for treating or preventing a proliferative disease using such a combination.